NEWS - Oct 15, 2019 Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression Read more
NEWS - Oct 14, 2019 Relmada Therapeutics to Announce Results of Phase 2 Study of REL-1017 for Treatment Resistant Depression and Conduct Conference Call on Tuesday, October 15 Read more
NEWS - Oct 10, 2019 Relmada Therapeutics Announces Commencement of Trading on The NASDAQ Capital Market Read more
NEWS - Sep 27, 2019 Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market Read more
NEWS - Jul 29, 2019 Relmada Therapeutics Announces Completion of Dosing with REL-1017 in Phase 2 Study of Individuals with Treatment Resistant Depression Read more
NEWS - Jun 3, 2019 Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles Read more
NEWS - May 31, 2019 Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting Read more
NEWS - Apr 16, 2019 Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results Read more
NEWS - Apr 3, 2019 Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations Read more
